失调
肝硬化
医学
肝病
微生物群
肝癌
疾病
肠道菌群
肝细胞癌
免疫学
生物信息学
胃肠病学
内科学
生物
作者
Maged El-Ghannam,Moataz Hassanien,Yosry Abdelrahman Ameen,Emad Abdelwahab Turky,Gamal Mohammed Elattar,Ahmed Aly ElRay,Mohammed Darwish Eltalkawy
标识
DOI:10.1016/j.clnesp.2022.12.030
摘要
Gut microbiota plays a crucial role in our health and particularly liver diseases, including NAFLD, cirrhosis, and HCC. Oral microbiome and its role in health and disease represent an active field of research. Several lines of evidence have suggested that oral microbiota dysbiosis represents a major factor contributing to the occurrence and progression of many liver diseases. The human microbiome is valuable to the diagnosis of cancer and provides a novel strategy for targeted therapy of HCC. The most studied liver disease in relation to oral–gut–liver axis dysbiosis includes MAFLD; however, other diseases include Precancerous liver disease as viral liver diseases, liver cirrhosis, AIH and liver carcinoma (HCC). It seems that restoring populations of beneficial organisms and correcting dysbiosis appears to improve outcomes in liver disorders. We discuss the possible role of oral microbiota in these diseases.
科研通智能强力驱动
Strongly Powered by AbleSci AI